Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2018

View Archived Issues

Retinoic acid has role in fragile X

RNA delivery improves CF symptoms

miRNA-126 and miRNA-223 found significantly increased in cardiac sarcoidosis

Hypermethylation variant silences BRCA1 gene

Upregulation of transgelin-2 by KRAS gene mutation contributes to pancreatic cancer development

Almac, Elasmogen and Innovate UK to develop VNAR-based oncology platform

Final results from PROPEL study support further clinical development of PTG-100 in UC

MediciNova, University of Cambridge to study ibudilast in degenerative cervical myelopathy

Researchers discover potent and selective histone deacetylase 11 inhibitors

First patient treated in phase I of HPN-424 in metastatic castration-resistant prostate cancer

Ovid Therapeutics reports topline data from STARS study in Angelman syndrome

Topical curcumin nanocarriers provide retinal protection in preclinical eye disease models

Aevitas Therapeutics, University of Pennsylvania enter sponsored research agreement

Mebias Discovery patents new compounds for pain

Lundbeck's Lu-AF82422 for Parkinson's enters the clinic

Japanese researchers synthesize new analgesic drugs

Angiochem reaches agreement on design of phase III study of ANG-1005

Novel long-range PCR method allows Ebola virus genome sequencing from ecological or clinical samples

NanoViricides' topical dermal shingles drug candidates show efficacy in rat model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...